Skip to main content

Table 5 Subgroup analyses for the outcome of overall survival

From: Influence of pre-transplant minimal residual disease on prognosis after Allo-SCT for patients with acute lymphoblastic leukemia: systematic review and meta-analysis

Subgroups No. of studies HR (95% CI) I2 (P value)
Population
 Adult 4 1.15 (0.86–1.53) 0 (0.73)
 Children 3 2.40 (1.49–3.89) 37.7% (0.20)
 Mixed adult and children 3 3.06 (1.98–4.70) 32.1% (0.23)
Design
 Prospective 6 1.68 (1.02–2.77) 60.1% (0.03)
 Retrospective 4 2.37 (1.55–3.63) 64.8% (0.04)
Region
 Europe 5 2.05 (1.10–3.80) 83.0% (< 0.01)
 USA 3 2.10 (1.50–2.94) 1.8% (0.36)
 Asia 2 1.89 (0.99–3.62) 0 (0.32)
Detection method
 PCR 6 1.65 (1.07–2.55) 61.5% (0.02)
 FC 4 2.53 (1.58–4.04) 58.1% (0.07)
Adjustment
 Adjusted 4 2.58 (1.27–5.26) 71.1% (0.02)
 Crude 6 1.70 (1.18–2.44) 58.7% (0.03)